Founded in 1984, Dr. Reddy’s Laboratories Limited is based in Hyderabad, India. Active pharmaceutical ingredients (APIs), custom pharmaceutical services (CPS), generics, biosimilars, and unique formulations are just a few of the goods and services provided by Dr. Reddy’s Laboratories Ltd., a well-known pharmaceutical firm with headquarters in India.
Dr. Reddy’s Laboratories – Quick Overview
| Particular | Details |
| Company Name | Dr. Reddy’s Laboratories Ltd. |
| Type | Public Listed Multinational Pharmaceutical Company |
| Industry | Pharmaceuticals – APIs, Generics, Biosimilars & OTC Products |
| Founded / Incorporated | 1984 |
| Founder | Dr. Kallam Anji Reddy |
| Headquarters | Hyderabad, Telangana, India |
| Key People | Kallam Satish Reddy (Chairman); G. V. Prasad (Co-Chairman & MD); Erez Israeli (CEO) |
| Core Business | Development, manufacture & marketing of pharmaceuticals, active pharmaceutical ingredients (APIs), biosimilars, OTC products & diagnostics |
| Major Products & Services | APIs, generic medicines, biosimilars, proprietary products, over-the-counter drugs, vaccines & diagnostics |
| Area Served | Worldwide (42+ countries) – India, USA, Europe, CIS, Latin America, Asia-Pacific |
| Manufacturing & R&D | Multiple global manufacturing sites with US FDA approvals; 8 global R&D centres |
| Employees | 26,000+ (approx.) |
| Market Position | One of India’s leading pharmaceutical firms with strong global presence |
| Stock Exchange Listing | BSE & NSE (Ticker: DRREDDY) – also historically listed on NYSE via ADRs |
| Business Segments | Global Generics; Pharmaceutical Services & Active Ingredients; Proprietary & Specialty Products |
| Recent Financial Highlights | Q3 FY26: Net profit ₹1,210 cr with modest revenue growth; mixed performance reflects competitive pressures. |
| Notable Initiatives | Focus on biosimilars, consumer health & digital therapeutics; global product launches (e.g., toripalimab, Elobixibat) and global generic filings. |
| Official Website | drreddys.com |
Net Worth and Market Cap
The market capitalization or net worth of Dr. Reddy’s Laboratories is INR 1.03 trillion. 1.02 trillion is the enterprise value.
Business Leadership
With its headquarters located in East Brunswick, New Jersey, Dr. Reddy’s Laboratories Ltd. is a worldwide pharmaceutical corporation based in Hyderabad, India. Kallam Anji Reddy created the business, and its major personnel include G. V. Prasad (co-chairman & MD), Kallam Satish Reddy (chairman), and Erez Israeli (CEO).
Overview of Services
In addition to manufacturing and selling finished pharmaceutical medicines under brand names or as generic final dosages with therapeutic equivalents to branded formulations, the Global Generics division is involved in the biologics industry.
The primary components of completed pharmaceutical goods, active pharmaceutical ingredients and intermediates, are produced and sold by the PSAI segment. In addition to manufacturing and selling steroids and active pharmaceutical ingredients in accordance with client specifications, this division offers contract research services.
Research and development of unique formulations, as well as the creation of treatments in the areas of inflammation and cancer, are the activities of the others segment. Gastrointestinal, cardiovascular, anti-diabetic, dermatological, oncology, respiratory, stomatology, urology, nephrology, vaccinations, and pain management are among the therapeutic categories for which the company sells its medicines.
Scale of Operations
In North America, Europe, India, Russia, and other countries, Dr. Reddy’s Laboratories Limited functions as an integrated pharmaceutical business with its affiliates. Pharmaceutical Services and Active Ingredients (PSAI), Others, and Global Generics are its operating segments. In India and abroad, Dr. Reddy produces and sells a variety of medications. The company manufactures more than 190 drugs and 60 active pharmaceutical ingredients (APIs) for use in biotechnology, critical care, diagnostic kits, and drug manufacturing.
